Lasme-cel Shows Promising Results in Relapsed/Refractory B-ALL

Cellectis' R&D Day highlights lasme-cel's potential to address significant unmet need in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) patients. The treatment achieved an ORR of 68% with lasme-cel Process 2, 83% at RP2D, and 100% in the target Phase 2 population. Safety was generally well-tolerated, and median OS was 14.8 months for MRD-negative CR/CRi patients. A Phase 2 pivotal trial has been initiated, with potential peak gross sales of up to $700 million across the US, EU4, and UK.